Investegate |COMPASS Pathways Announcements | COMPASS Pathways: COMPASS Pathways announces further positive results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression
Investegate announcements from COMPASS Pathways, COMPASS Pathways announces further positive results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression